Neural O
responses O
to O
negative O
outcomes O
predict O
success O
in O
community-based O
substance O
use O
treatment O
Background O
and O
aims O
Activation O
in O
some O
specific O
brain O
regions O
has O
demonstrated O
promise O
as O
prognostic O
indicators O
in O
substance O
dependent O
individuals O
( O
SDIs O
) O
but O
this O
issue O
has O
not O
yet O
been O
explored O
in O
SDIs O
attending O
typical O
of O
community-based O
treatment O
. O

We O
used O
a O
data-driven O
, O
exploratory O
approach O
to O
identify O
brain-based O
predictors O
of O
treatment O
outcome O
in O
a O
representative O
community O
sample O
of O
SDIs O
. O

The O
predictive O
utility O
of O
brain-based O
measures O
was O
evaluated O
against O
clinical O
indicators O
, O
cognitive-behavioral O
performance O
, O
and O
self-report O
assessments O
. O

Design O
Prospective O
clinical O
outcome O
design O
, O
evaluating O
baseline O
functional O
magnetic O
resonance O
imaging O
data O
from O
the O
Balloon O
Analogue O
Risk O
Task O
( O
BART O
) O
as O
a O
predictor O
of O
3-month O
substance O
use O
treatment O
outcomes O
. O

Setting O
Community-based O
substance O
use O
programs O
in O
Bloomington O
, O
Indiana O
, O
USA O
. O

Participants O
Twenty-three O
SDIs O
( O
17 O
male O
, O
ages O
18–43 O
) O
in O
an O
intensive O
outpatient O
or O
residential O
treatment O
program O
; O
abstinent O
1–4 O
weeks O
at O
baseline O
. O

Measurements O
Event-related O
brain O
response O
, O
BART O
performance O
, O
and O
self-report O
scores O
at O
treatment O
onset O
, O
substance O
use O
outcome O
measure O
( O
based O
on O
days O
of O
use O
) O
Findings O
Using O
voxel-level O
predictive O
modeling O
and O
leave-one-out O
cross-validation O
, O
an O
elevated O
response O
to O
unexpected O
negative O
feedback O
in O
bilateral O
amygdala O
and O
anterior O
hippocampus O
( O
Amyg/aHipp O
) O
at O
baseline O
successfully O
predicted O
greater O
substance O
use O
over O
the O
3-month O
study O
interval O
( O
p O
≤ O
0.006 O
, O
cluster-corrected O
) O
. O

This O
effect O
was O
robust O
to O
inclusion O
of O
significant O
non-brain-based O
covariates O
. O

A O
larger O
response O
to O
negative O
feedback O
in O
bilateral O
Amyg/aHipp O
was O
also O
associated O
with O
faster O
reward-seeking O
responses O
after O
negative O
feedback O
( O
r O
( O
23 O
) O
= O
−0.544 O
, O
p O
= O
0.007 O
; O
r O
( O
23 O
) O
= O
−0.588 O
, O
p O
= O
0.003 O
) O
. O

A O
model O
including O
Amyg/aHipp O
activation O
, O
faster O
reward-seeking O
after O
negative O
feedback O
, O
and O
significant O
self-report O
scores O
accounted O
for O
45 O
% O
of O
the O
variance O
in O
substance O
use O
outcomes O
in O
our O
sample O
. O

Conclusions O
An O
elevated O
response O
to O
unexpected O
negative O
feedback O
in O
bilateral O
amygdala O
and O
anterior O
hippocampus O
( O
Amyg/aHipp O
) O
appears O
to O
predict O
relapse O
to O
substance O
use O
in O
people O
attending O
community-based O
treatment O
. O

Methods O
Design O
We O
utilized O
a O
prospective O
clinical O
outcome O
design O
. O

Neuroimaging O
, O
cognitive-behavioral O
, O
and O
self-report O
measures O
were O
collected O
at O
the O
beginning O
of O
treatment O
and O
examined O
as O
candidate O
predictors O
of O
three-month O
substance O
use O
outcomes O
. O

Participants O
Twenty-six O
SDIs O
were O
enrolled O
upon O
engagement O
with O
community-based O
treatment O
and O
assessed O
within O
1–4 O
weeks O
of O
self-reported O
abstinence O
; O
a O
sample O
of O
23 O
( O
ages O
18–43 O
) O
was O
followed O
for O
3 O
months O
( O
see O
Table O
1 O
for O
demographic O
and O
recruitment O
data O
) O
. O

Participants O
received O
treatment-as-usual O
through O
one O
of O
two O
abstinence-oriented O
, O
community-based O
addiction O
treatment O
programs O
( O
one O
intensive O
outpatient O
and O
one O
residential O
program O
; O
see O
Supporting O
Materials O
for O
additional O
information O
) O
and O
were O
not O
receiving O
replacement O
pharmacotherapy O
. O

All O
met O
DSM-IV O
criteria O
for O
alcohol O
, O
drug O
, O
or O
polysubstance O
dependence O
, O
without O
history O
of O
traumatic O
brain O
injury O
, O
neurocognitive O
disorders O
, O
Bipolar O
, O
or O
psychotic O
illness O
. O

An O
electronic O
breathalyzer O
and O
6-panel O
urine O
drug O
screen O
were O
conducted O
at O
baseline O
and O
3-month O
follow-up O
; O
behavioral O
signs O
of O
intoxication O
were O
also O
evaluated O
. O

Assessments O
were O
only O
conducted O
if O
blood O
alcohol O
content O
was O
0.000 O
percent O
by O
volume O
, O
urinalysis O
was O
negative O
for O
illicit O
substances O
, O
and O
behavioral O
signs O
of O
intoxication O
were O
absent O
. O

Participants O
provided O
written O
informed O
consent O
; O
all O
methods O
were O
approved O
by O
the O
Indiana O
University O
Institutional O
Review O
Board O
. O

fMRI O
Acquisition O
and O
BART O
Procedure O
Imaging O
data O
were O
acquired O
at O
baseline O
and O
3-month O
follow-up O
using O
a O
32-channel O
head O
coil-equipped O
, O
Siemens O
Magnetom O
Trio O
3-Tesla O
MRI O
scanner O
; O
follow-up O
data O
are O
reported O
elsewhere O
. O

Echo-planar O
gradient-echo O
T2 O
* O
-weighted O
sequences O
of O
240 O
whole-brain O
volumes O
measured O
the O
functional O
blood-oxygen-level-dependent O
( O
BOLD O
) O
response O
during O
two O
eight-minute O
blocks O
of O
BART O
( O
see O
Figure O
1 O
) O
. O

Acquisition O
, O
task O
, O
and O
preprocessing O
parameters O
were O
identical O
to O
previous O
work O
; O
details O
provided O
in O
Supporting O
Information O
. O

In O
brief O
, O
the O
BART O
involved O
button-press O
responses O
to O
either O
‘ O
Inflate O
’ O
a O
balloon O
– O
incrementally O
and O
quasi-exponentially O
increasing O
its O
size O
and O
value O
in O
parallel O
with O
the O
probability O
of O
explosion O
– O
or O
‘ O
Redeem O
’ O
it O
for O
its O
current O
value O
. O

Stimuli O
were O
presented O
using O
E-Prime O
( O
Psychology O
Software O
Tools O
, O
Pittsburgh O
, O
PA O
) O
; O
a O
projector O
was O
used O
for O
display O
within O
the O
scanner O
bore O
. O

Trials O
began O
with O
an O
image O
of O
a O
balloon O
. O

A O
red O
rectangle O
was O
presented O
for O
1.5–2.5 O
seconds O
, O
indicating O
to O
wait O
before O
responding O
and O
subsequently O
turned O
green O
, O
indicating O
to O
respond O
when O
ready O
. O

Participants O
responded O
with O
left O
or O
right O
index O
fingers O
( O
response-mapping O
counterbalanced O
across O
subjects O
) O
. O

Each O
balloon O
sequence O
began O
with O
a O
balloon O
worth O
$ O
0.00 O
. O

After O
each O
response O
, O
a O
jittered O
delay O
of O
0–6 O
seconds O
preceded O
feedback O
( O
‘ O
Successful_Gamble O
’ O
, O
‘ O
Explode O
’ O
, O
‘ O
Confirmed_Gain O
’ O
) O
such O
that O
the O
BOLD O
response O
could O
be O
estimated O
separately O
for O
decision O
and O
outcome O
intervals O
. O

‘ O
Inflate O
’ O
responses O
could O
result O
in O
either O
1 O
) O
a O
‘ O
Successful_Gamble O
, O
’ O
whereupon O
the O
display O
was O
updated O
with O
a O
larger O
balloon O
and O
increased O
wager O
value O
, O
initiating O
the O
next O
decision O
or O
2 O
) O
‘ O
Explode O
’ O
feedback O
, O
indicating O
loss O
of O
the O
current O
wager O
. O

‘ O
Redeem O
’ O
responses O
always O
resulted O
in O
‘ O
Confirmed_Gain O
’ O
feedback O
and O
addition O
of O
the O
balloon O
value O
to O
block O
winnings O
( O
visible O
at O
bottom O
of O
screen O
) O
. O

Participants O
completed O
an O
average O
of O
95 O
decision O
trials O
and O
16 O
balloon O
sequences O
per O
block O
. O

Additional O
Measures O
The O
timeline O
follow-back O
procedure O
was O
administered O
at O
1- O
, O
2- O
, O
and O
3-month O
timepoints O
to O
document O
drug O
and O
alcohol O
use O
during O
the O
study O
interval O
. O

Narrative O
details O
of O
use O
( O
e.g. O
, O
subjective O
intoxication O
) O
were O
also O
acquired O
. O

Details O
of O
the O
timeline O
follow-back O
procedure O
, O
as O
well O
as O
psychodiagnostic O
, O
self-report O
, O
and O
cognitive-behavioral O
assessments O
are O
provided O
in O
Supporting O
Information O
. O

fMRI O
Analysis O
Imaging O
data O
were O
analyzed O
using O
SPM5 O
and O
Matlab O
R2013a O
. O

BART O
BOLD O
responses O
were O
estimated O
using O
a O
general O
linear O
model O
with O
20 O
regressors O
: O
six O
motion O
regressors O
, O
two O
constants O
, O
five O
main O
effect O
regressors O
( O
‘ O
Redeem O
’ O
, O
‘ O
Inflate O
’ O
, O
‘ O
Explode O
’ O
, O
‘ O
Successful_Gamble O
’ O
, O
‘ O
Confirmed_Gain O
’ O
) O
, O
five O
parametric O
modulators O
representing O
explosion O
probability O
for O
each O
event O
, O
and O
2 O
parametric O
modulators O
representing O
‘ O
Redeem O
’ O
and O
‘ O
Inflate O
’ O
response O
times O
( O
RTs O
) O
. O

A O
canonical O
hemodynamic O
response O
function O
was O
used O
to O
model O
event-related O
signals O
during O
decision O
( O
i.e. O
, O
RT O
) O
and O
outcome O
( O
i.e. O
, O
feedback O
onset O
) O
intervals O
. O

Subject O
was O
included O
as O
a O
random O
effect O
at O
the O
second-level O
. O

Contrasts O
isolated O
effects O
associated O
with O
negative O
outcomes O
over O
uncertain O
( O
‘ O
Explode O
– O
Successful_Gamble O
’ O
) O
and O
certain O
gains O
( O
‘ O
Explode O
– O
Confirmed_Gain O
’ O
) O
, O
decisions O
to O
pursue O
uncertain O
gains O
( O
‘ O
Inflate O
– O
Redeem O
’ O
) O
, O
and O
decisions O
to O
pursue O
certain O
gains O
( O
‘ O
Redeem O
– O
Inflate O
’ O
) O
, O
as O
well O
as O
regions O
in O
which O
trial-to-trial O
fluctuations O
in O
BOLD O
signal O
correlated O
with O
the O
probability O
of O
explosion O
( O
i.e O
. O

parametric O
modulators O
, O
designated O
by O
‘ O
* O
p O
( O
Explode O
) O
’ O
) O
. O

Using O
a O
cluster-forming O
threshold O
of O
p O
< O
0.001 O
, O
clusters O
of O
30 O
or O
more O
voxels O
with O
a O
cluster-corrected O
p-value O
of O
< O
0.05 O
, O
were O
identified O
as O
regions O
of O
interest O
( O
ROIs O
) O
. O

The O
cluster-extent O
threshold O
was O
determined O
using O
AFNI O
’ O
s O
3dClustSim O
to O
provide O
a O
type O
I O
error O
rate O
of O
α O
= O
0.005 O
. O

Two O
participants O
were O
excluded O
from O
the O
second-level O
‘ O
Explode O
* O
p O
( O
Explode O
) O
’ O
contrast O
because O
low O
explosion O
frequency O
precluded O
unique O
specification O
in O
the O
first-level O
general O
linear O
model O
. O

Whole-brain O
correlational O
analyses O
were O
conducted O
for O
each O
contrast O
to O
identify O
regions O
in O
which O
task-related O
activity O
was O
associated O
with O
substance O
use O
during O
the O
study O
interval O
. O

A O
substance O
use O
metric O
( O
SUM O
) O
was O
calculated O
from O
timeline O
follow-back O
data O
for O
each O
participant O
, O
representing O
incidents O
of O
drug O
and O
alcohol O
use O
during O
the O
study O
, O
weighted O
by O
presence/absence O
of O
intoxication O
; O
1 O
a O
log-odds O
transformation O
was O
applied O
prior O
to O
analysis O
. O

This O
approach O
was O
chosen O
to O
better O
capture O
variability O
in O
substance O
use O
outcomes O
within O
the O
study O
sample O
( O
see O
Supporting O
Information O
) O
. O

Next O
, O
voxel-level O
predictive O
modeling O
and O
leave-one-out O
cross-validation O
were O
used O
to O
identify O
ROIs O
predictive O
of O
substance O
use O
outcomes O
and O
compare O
performance O
of O
models O
based O
on O
brain- O
and/or O
non-brain-based O
predictors O
( O
see O
Supporting O
Information O
for O
details O
) O
. O

Briefly O
, O
linear O
regression O
was O
applied O
with O
cross-validation O
on O
a O
voxel-by-voxel O
basis O
. O

Clusters O
wherein O
constituent O
voxels O
yielded O
predicted O
SUM O
values O
for O
left-out O
participants O
that O
strongly O
correlated O
with O
actual O
SUM O
values O
were O
targeted O
for O
further O
investigation O
. O

Leave-one-out O
cross-validation O
was O
selected O
for O
optimism-correction O
because O
this O
approach O
has O
been O
recommended O
for O
small O
neuroimaging O
datasets O
and O
used O
in O
similar O
work O
with O
a O
comparable O
sample O
size O
. O

Predictive O
analysis O
of O
binary O
treatment O
outcomes O
was O
also O
conducted O
using O
Receiver O
Operating O
Characteristic O
curves O
and O
is O
described O
in O
Supporting O
Information O
and O
Figure O
S1 O
. O

Analysis O
of O
Cognitive-behavioral O
and O
Self-Report O
Measures O
Pearson O
correlations O
with O
the O
substance O
use O
outcome O
variable O
( O
i.e. O
, O
SUM O
) O
were O
calculated O
for O
each O
measure O
. O

Paired O
t-tests O
and O
repeated O
measures O
analysis O
of O
variance O
( O
ANOVA O
) O
were O
utilized O
for O
comparisons O
between O
conditions O
, O
as O
necessary O
. O

Statistics O
were O
computed O
in O
SPSS O
. O

Self-report O
and O
behavioral O
findings O
for O
cognitive-behavioral O
tasks O
other O
than O
BART O
are O
summarized O
in O
Supporting O
Information O
and O
Table O
S1 O
. O

